Business Location Switzerland’s Post

🤝 A total of 45 companies and organizations have already joined the Advanced Therapies Network of Catalonia, a project the Government of Catalonia entrusted to #Biocat in order to get these therapies to patients faster and project the #BioRegionCatalonia as a global benchmark hub in advanced therapies. 🚀 The ecosystem has great potential in this field, but it is important to tackle some of the challenges such us: ☑ Training and retaining talent ☑ Technology transfer and acceleration of projects and companies ☑ Scale up and market access for this type of drugs ☑ Relations with the healthcare system ☑ Public-private partnerships Learn more about the next steps for ATMP Catalonia: 👇 atmpcatalonia.cat

𝗧𝗵𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗿𝗶𝘀𝗶𝘀 𝗼𝗳 𝟮𝟬𝟮𝟮 𝘂𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱𝗹𝘆 𝘁𝘂𝗿𝗻𝗲𝗱 𝗶𝗻𝘁𝗼 𝗮 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲. 𝗛𝗼𝘄 𝗱𝗶𝗱 𝘁𝗵𝗶𝘀 𝗵𝗮𝗽𝗽𝗲𝗻? In 2023, the Swiss biotech sector saw a significant rebound from the previous year, as highlighted in the Swiss Biotech Report: https://swiy.co/MkC2 The slowdown in 2022 forced Swiss biotech companies to shift their focus from purely financial to business-development partners. As a result, in 2023, there was more than 𝟱𝟬% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 compared to 2022, though this benefit was only seen by a handful of companies. Numerous firms received little to no financial backing at all. Faced with high perceived risk by investors and fewer chances to raise funds, companies had to rethink their business strategies, focusing more on reaching out directly to their customers or end-users. This trend persisted into 2024 for companies at Biopôle Lausanne. In just 4 four months this year, 5 CH companies secured over $110 million in total from investors. Even more impressively, this year saw 15 strategic deals, including 10 partnerships or business development agreements with biotech market leaders and the launch of 5 new products. Companies such as PeriVision, NewBiologix, Aspivix, Orbis Medicines, and Testmate Health stand out in this regard. It’s time for the industry to move beyond just financial metrics and crises to adopt a broader view. Considering other key performance indicators like new client acquisition, product launches, and deal signings, should be taken seriously to better evaluate the industry's performance and its contributions. More insights? Feel free to sign up and join up to 1500 members : swiy.co/NWng #biopharma #marketinsights #scaleups

Latin America: The hidden gem of Medtech clinical trials? 💎 I've seen firsthand how countries like Colombia and Mexico are transforming the research landscape. Diverse patient populations + improving infrastructure = game-changing potential. But it's not just about numbers. It's about impact. Example: A recent trial in Chile recruited patients 30% faster than the global average. This isn't just good for business. It's accelerating life-saving innovations. What's your experience with LatAm clinical trials? #MedTech #ClinicalTrials #bioaccess

Less than 4 weeks to go until our LSX USA Congress takes place in Boston (11th-12th Sept)! Next panel we'd like to highlight is.. 📣 The Convergence of Biopharma, Medtech & Healthtech – What Does This Mean for The Future of Healthcare Delivery? Join our panel of experts as they discuss: 📌Investor perspective- building a thriving ecosystem that combines startups from all three verticals 📌Going beyond ‘AI in drug discovery’ and bridging the gap between Healthtech & Biopharma 📌Discussing how the integration of digital and medical technologies is enhancing diagnostics and monitoring 📌Data – How is the industry leveraging all the patient data whilst addressing privacy concerns? 📌Real-world examples of personalized care facilitated by this convergence 🎙 Hear from: 🎤Moderator: Oliver Barnes, US Pharma & Biotech Correspondent, Financial Times Christopher Leggett, Head of Market Transformation, Vertex Pharmaceuticals Paul Geevarghese, Co-Founder & COO, 9amHealth Jim Parshall, Executive Director, Delivery Device R&D, Eli Lilly and Company Naomi Fried, Ph.D. Fried, CEO & Founder, PharmStars Jeff Chu, Managing Partner, Features Capital Find out more: https://bit.ly/4eEbT9j #LSXUSA #DigitalHealth #Medtech #Biotech

The intersection and overlap between BioTech, MedTech, and HealthTech has never been greater. Looking forward to sharing some thoughts and insights around this at #LSXUSA. Hope to see you there. #MedTech #Innovation #UnlockMedTech #AccelerateFutureOfHealthcare

The value of FDI companies in Ireland is significant, not only to GDP but also to the effect on the ecosystem and the positive impact it has on our SMEs in the value chain. Talent and upskilling is a key part of Ireland’s value proposition to attracting and retaining FDI and we need to continue our high quality digital and sustainable skills provision across the skills ecosystem. #upskilling #collaboration #partnership #digitalisation #sustainability #competitiveadvantage

💹 Investment in #DigitalHealth increases in the #BioRegionCatalonia, despite the global context: while global investment in digital health experienced a decline in 2023, Catalonia defied the trend, increasing by 61% compared to the previous year. This growth was primarily attributed to three key operations 💰: Qida (home-care) (€18 M), IOMED (€10 M), and Top Doctors (€8 M). ⬆ The #biotech subsector is the primary segment attracting #funding, surpassing 110M€ in 2023. Notable operations include those of 💰 SOM Biotech (€17 M), Nuage Therapeutics (€12 M), and Oryzon Genomics SA (€8 M). ⬇ The #medtech subsector, although facing a decline, has successfully rebounded to #investment levels seen before 2021. The most significant operations in this subsector were 💰 INBRAIN Neuroelectronics (€20 M), ADmit Therapeutics (€5.4 M), and deepull (€4 M). More data in the #BioRegionReport: https://report.biocat.cat/ Promoted by: Biocat, BioRegion of Catalonia With the support of: Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi. In collaboration with: CataloniaBio & HealthTech, ACCIÓ, Farmaindustria, and Fenin, Federación Española de Empresas de Tecnología Sanitaria.

Booming Basel, Top CROs, Mexico's clinical trial ingredients & ISPOR's 2030 vision...This week on PharmaBoardroom 💡 Christof Kloepper of Basel Area Business & Innovation delves into the Basel Area’s positioning as a leading hub for life sciences and biotech innovation. Kloepper emphasizes the region's commitment to attracting global companies, nurturing startups, and building a strong ecosystem of talent, research, and infrastructure https://lnkd.in/d8T4FqWw 🔟 An overview of ten of the companies dominating the global CRO landscape in 2024 https://lnkd.in/dtkc7FJA 🔬 Jorge Luis Caridad of Johnson & Johnson Innovative Medicine discusses the company’s commitment to collaboratively advancing innovation in Mexico, including through digitalisation and clinical trials https://lnkd.in/dNwEvwjh 👀 Against the backdrop of a global push to make healthcare more accessible and affordable, ISPOR—The Professional Society for Health Economics and Outcomes Research's Rob Abbott introduces the organisation’s 2030 strategy, focused on achieving health system sustainability around the world https://lnkd.in/dPbDCnbp

Ireland offers an ecosystem that encompasses innovation, focuses on talent, and is committed to supporting client sustainability and digital transformation. The MedTech sector in Ireland is going from strength to strength. New centres of excellence such as Digital Manufacturing Ireland, have been established by the Irish Government to assist Irish-based manufacturers in rapidly adopting digital technologies to transform their value chains.    MedTech exports from Ireland are worth more than €13bn a year – 8% of the country’s total exports. Ireland’s talent pool, collaboration amongst research centres and universities, as well as connectivity to Europe are some of the key reasons why industry-leaders such as Dexcom, MeiraGTx and Regeneron have come to Ireland. Learn more here: https://lnkd.in/e7sZRb_6 #InvestInIreland #InvestInExtraordinary #MedTech #Innovation #Talent

📍 #Catalonia is #health, #innovation, and #talent. It is, indeed, one of the leading #healthcare innovation hubs in Europe. Do you know what makes it so competitive❓ Here are some Facts & Figures from the #BioRegionCatalonia: 💰 Over €42 billion in turnover (7.9% of GDP) 👩⚕️ Close to 264,000 jobs (6.5% of the employed population) 🌎 €8.85 billion in product exports from the sector 📈 €1.7 billion in foreign investment from 2019-2023 (4,700 new jobs) 🚀 €220 million invested in startups and scale-ups 💊 5,300 active clinical trials (5th in Europe and 8th worldwide) ⚗ 73 therapies in clinical development, 19 of them Advanced Therapies Check the #BioRegionReport 2023 for more data: 📋 https://report.biocat.cat/ The Bioregion Report has been published by #Biocat since 2009. This edition had the support of Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi. And the collaboration of CataloniaBio & HealthTech, ACCIÓ, Farmaindustria, and Fenin, Federación Española de Empresas de Tecnología Sanitaria.